John A. Taylor

3.0k total citations
84 papers, 2.0k citations indexed

About

John A. Taylor is a scholar working on Surgery, Molecular Biology and Urology. According to data from OpenAlex, John A. Taylor has authored 84 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Surgery, 32 papers in Molecular Biology and 14 papers in Urology. Recurrent topics in John A. Taylor's work include Bladder and Urothelial Cancer Treatments (43 papers), Urinary and Genital Oncology Studies (18 papers) and Epigenetics and DNA Methylation (13 papers). John A. Taylor is often cited by papers focused on Bladder and Urothelial Cancer Treatments (43 papers), Urinary and Genital Oncology Studies (18 papers) and Epigenetics and DNA Methylation (13 papers). John A. Taylor collaborates with scholars based in United States, France and United Kingdom. John A. Taylor's co-authors include George A. Kuchel, Benjamin L. Woolbright, Ashish M. Kamat, Carol C. Pilbeam, Ganeshkumar Rajendran, Thomas W. Flaig, Robert A. Harris, Badrinath R. Konety, Michael A. O’Donnell and Donald L. Lamm and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

John A. Taylor

79 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John A. Taylor United States 25 846 701 420 299 299 84 2.0k
Phei‐Lang Chang Taiwan 25 495 0.6× 732 1.0× 566 1.3× 224 0.7× 108 0.4× 87 1.9k
Yoshiyuki Matsui Japan 27 1.0k 1.2× 679 1.0× 733 1.7× 444 1.5× 134 0.4× 178 2.6k
Yuki Tobisawa Japan 26 651 0.8× 737 1.1× 525 1.3× 232 0.8× 224 0.7× 130 2.0k
Toru Shimazui Japan 27 638 0.8× 1.1k 1.6× 465 1.1× 301 1.0× 98 0.3× 111 2.3k
Miao‐Fen Chen Taiwan 30 770 0.9× 580 0.8× 503 1.2× 844 2.8× 396 1.3× 88 2.4k
Kesavan Esuvaranathan Singapore 22 558 0.7× 569 0.8× 304 0.7× 145 0.5× 255 0.9× 64 1.3k
Xiaokun Zhao China 23 348 0.4× 903 1.3× 352 0.8× 257 0.9× 144 0.5× 97 1.8k
Bo Peng China 26 254 0.3× 919 1.3× 376 0.9× 326 1.1× 89 0.3× 119 1.9k
Bin Sun China 31 299 0.4× 1.1k 1.6× 418 1.0× 707 2.4× 293 1.0× 94 3.0k
Charles M. Quick United States 28 315 0.4× 530 0.8× 426 1.0× 272 0.9× 201 0.7× 92 2.2k

Countries citing papers authored by John A. Taylor

Since Specialization
Citations

This map shows the geographic impact of John A. Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Taylor more than expected).

Fields of papers citing papers by John A. Taylor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Taylor. The network helps show where John A. Taylor may publish in the future.

Co-authorship network of co-authors of John A. Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Taylor. A scholar is included among the top collaborators of John A. Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Taylor. John A. Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taylor, John A., et al.. (2024). Understanding the microbiome as a mediator of bladder cancer progression and therapeutic response. Urologic Oncology Seminars and Original Investigations. 43(4). 254–265. 1 indexed citations
2.
Woolbright, Benjamin L., et al.. (2023). Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer. Cancers. 15(6). 1654–1654. 4 indexed citations
3.
Sun, Yajing, Ze Lu, John A. Taylor, & Jessie L.‐S. Au. (2023). Quantitative image analysis of intracellular protein translocation in 3-dimensional tissues for pharmacodynamic studies of immunogenic cell death. Journal of Controlled Release. 365. 89–100.
4.
5.
Woolbright, Benjamin L., et al.. (2022). Role of MIF1 / MIF2 / CD74 interactions in bladder cancer. The Journal of Pathology. 259(1). 46–55. 16 indexed citations
6.
Weir, Scott J., Prasad Dandawate, David Standing, et al.. (2021). Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex. Cell Death and Disease. 12(6). 562–562. 11 indexed citations
7.
Dennis, Katie, et al.. (2020). Near-Miss Diagnoses of Solitary Bladder Tumors Highlight the Importance of Immunohistochemical Staining. SHILAP Revista de lepidopterología. 2020. 1–3. 1 indexed citations
8.
Weir, Scott J., Amanda E. Brinker, Prabhu Ramamoorthy, et al.. (2019). Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. Journal of Pharmacology and Experimental Therapeutics. 370(2). 148–159. 17 indexed citations
9.
Liu, Weiya, Benjamin L. Woolbright, Gaurav Kaushik, et al.. (2019). Tumor M2-PK: A novel urine marker of bladder cancer. PLoS ONE. 14(6). e0218737–e0218737. 16 indexed citations
10.
Woolbright, Benjamin L., et al.. (2018). The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance. Molecular Cancer Therapeutics. 17(9). 2004–2012. 83 indexed citations
11.
Smilowitz, Henry M., et al.. (2017). Biodistribution of gold nanoparticles in BBN-induced muscle-invasive bladder cancer in mice. International Journal of Nanomedicine. Volume 12. 7937–7946. 10 indexed citations
12.
Flaig, Thomas W., Ashish M. Kamat, Donna E. Hansel, et al.. (2017). Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer. 3(3). 211–223. 3 indexed citations
13.
Kamat, Ashish M., Joaquim Bellmunt, Matthew D. Galsky, et al.. (2017). Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Journal for ImmunoTherapy of Cancer. 5(1). 68–68. 60 indexed citations
14.
Choudhary, Dharamainder, Jessica Clement, Shilpa Choudhary, et al.. (2017). SATB1 and bladder cancer: Is there a functional link?. Urologic Oncology Seminars and Original Investigations. 36(3). 93.e13–93.e21. 9 indexed citations
15.
Garg, Isha, et al.. (2016). AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27. Molecular Cancer Research. 14(12). 1182–1194. 18 indexed citations
16.
Hegde, Poornima, et al.. (2016). AMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms. Translational Oncology. 9(6). 606–616. 12 indexed citations
17.
Kamat, Ashish M., Antonia Vlahou, John A. Taylor, et al.. (2014). Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 32(7). 1069–1077. 27 indexed citations
18.
Schmitz‐Dräger, Bernd J., Tilman Todenhöfer, Bas van Rhijn, et al.. (2014). Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 32(7). 1061–1068. 27 indexed citations
19.
Taylor, John A., et al.. (2014). Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Current Opinion in Urology. 24(5). 512–516. 4 indexed citations
20.
Taylor, John A. & George A. Kuchel. (2006). Detrusor Underactivity: Clinical Features and Pathogenesis of an Underdiagnosed Geriatric Condition. Journal of the American Geriatrics Society. 54(12). 1920–1932. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phei‐Lang Chang Breakdown of academic impact, for papers by Yoshiyuki Matsui Breakdown of academic impact, for papers by Yuki Tobisawa Breakdown of academic impact, for papers by Toru Shimazui Breakdown of academic impact, for papers by Miao‐Fen Chen Breakdown of academic impact, for papers by Kesavan Esuvaranathan Breakdown of academic impact, for papers by Xiaokun Zhao Breakdown of academic impact, for papers by Bo Peng Breakdown of academic impact, for papers by Bin Sun Breakdown of academic impact, for papers by Charles M. Quick
Rankless by CCL
2026